Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7.
CAS
PubMed
Google Scholar
Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.
Article
CAS
PubMed
Google Scholar
Bishop PC, Rao VK, Wilson WH. Burkitt’s lymphoma: molecular pathogenesis and treatment. Cancer Invest. 2000;18:574–83.
Article
CAS
PubMed
Google Scholar
Jang SJ, Yoon DH, Kim S, Yoon S, Kim DY, Park CS, et al. A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single centerexperience. Ann Hematol. 2012;91:1917–22.
Article
CAS
PubMed
Google Scholar
Rowe M, Fitzsimmons L, Bell AI. Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer. 2014;33:609–19.
PubMed Central
CAS
PubMed
Google Scholar
Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, et al. Clinicopathologic features and Epstein-Barr virus infection status of Burkitt’s lymphoma in Guangzhou district. Ai Zheng. 2009;28:805–12 [in Chinese].
CAS
PubMed
Google Scholar
Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematol Am Soc Hematol Educ Program. 2008:341–8. doi:10.1182/asheducation-2008.1.341.
Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D’Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24:1879–86.
Article
PubMed
Google Scholar
Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507–16.
Article
CAS
PubMed
Google Scholar
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
Article
PubMed
Google Scholar
Zhang X, Fan W, Hu YY, Li ZM, Xia ZJ, Lin XP, et al. Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma. Chin J Cancer. 2015;34:20.
Article
PubMed Central
Google Scholar
Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.
Article
CAS
PubMed
Google Scholar
Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of midtherapy positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.
Article
CAS
PubMed
Google Scholar
Li YJ, Li ZM, Xia XY, Huang HQ, Xia ZJ, Lin TY, et al. Prognostic value of midtherapy and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med. 2013;54:507–15.
Article
CAS
PubMed
Google Scholar
Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008;22:695–700.
Article
PubMed
Google Scholar
Kyoung Jung H, Kim EK, Yun M, Jung Kim M, Young Kwak J. Bilateral breasts involvement in Burkitt lymphoma detected only by FDG-PET. Clin Imaging. 2006;30:57–9.
Article
PubMed
Google Scholar
Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R. Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med. 2009;34:355–8.
Article
PubMed
Google Scholar
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
Article
PubMed
Google Scholar
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.
Article
PubMed
Google Scholar
Barrington SF, Carr R. Staging of Burkitt’s lymphoma and response to treatment monitored by PET scanning. Clin Oncol (R Coll Radiol). 1995;7:334–5.
Article
CAS
Google Scholar
Chander S, Webster GC, Zingas AP, Zak IT, Joyrich RN, Zerin JM, et al. American Burkitt lymphoma of the head and neck: evaluation with serial FDG-PET. Clin Nucl Med. 2004;29:646–8.
Article
PubMed
Google Scholar
Ford CD, Gabor F, Morgan R, Dabbas B. False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma. Clin Nucl Med. 2006;31:391–3.
Article
PubMed
Google Scholar
Wang X, Chen Z, Tang G, Zhang X. A child with Burkitt lymphoma with pleural, peritoneal, mesenteric, omental, and renal involvement: diagnostics by FDG PET/CT. Clin Nucl Med. 2011;36:612–5.
Article
PubMed
Google Scholar
Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.
Article
PubMed
Google Scholar
Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, et al. 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol. 2010;75:e68–73.
Article
PubMed
Google Scholar
Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDGPET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160–8.
Article
CAS
PubMed
Google Scholar
Chihara D, Oki Y, Onoda H, Taji H, Yamamoto K, Tamaki T, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol. 2011;93:502–8.
Article
PubMed
Google Scholar
Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of midtherapy 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.
Article
PubMed
Google Scholar
Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–32.
Article
PubMed
Google Scholar
Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690–6.
Article
PubMed
Google Scholar
Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386–92.
Article
PubMed Central
PubMed
Google Scholar